These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 108704)

  • 1. Quipazine-induced stimulus control in the rat.
    Winter JC
    Psychopharmacology (Berl); 1979 Feb; 60(3):265-9. PubMed ID: 108704
    [No Abstract]   [Full Text] [Related]  

  • 2. The actions of neuroleptic drugs and putative serotonin receptor antagonists on LSD and quipazine-induced reductions of brain 5-HIAA concentrations.
    Jacoby JH; Poulakos JJ
    J Pharm Pharmacol; 1977 Dec; 29(12):771-3. PubMed ID: 22629
    [No Abstract]   [Full Text] [Related]  

  • 3. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
    Friedman RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1984 Mar; 228(3):628-35. PubMed ID: 6707913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist.
    Colpaert FC; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1982 Apr; 221(1):206-14. PubMed ID: 7062283
    [No Abstract]   [Full Text] [Related]  

  • 5. Behavioral interactions of opioid agonists and antagonists with serotonergic systems.
    Rech RH; Mokler DJ; Commissaris RL; Henck JW
    NIDA Res Monogr; 1984 Mar; 49():179-84. PubMed ID: 6434957
    [No Abstract]   [Full Text] [Related]  

  • 6. Head twitches induced by LSD and quipazine: similarities and differences.
    Vetulani J; Bednarczyk B; Reichenberg K; Rokosz A
    Neuropharmacology; 1980 Feb; 19(2):155-8. PubMed ID: 6244515
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of quipazine on pre- and postsynaptic serotonin receptors: single cell studies in the rat CNS.
    Blier P; de Montigny C
    Neuropharmacology; 1983 Apr; 22(4):495-9. PubMed ID: 6856049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naloxone alters the effects of LSD, DOM and quipazine on operant behavior of rats.
    Mokler DJ; Commissaris RL; Henck JW; Rech RH
    Pharmacol Biochem Behav; 1984 Sep; 21(3):333-7. PubMed ID: 6593750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evidence of partial agonist activity exerted by purported 5-hydroxytryptamine antagonists.
    Colpaert FC; Niemegeers CJ; Janssen PA
    Eur J Pharmacol; 1979 Oct; 58(4):505-9. PubMed ID: 510385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine.
    Fiorella D; Helsley S; Rabin RA; Winter JC
    Psychopharmacology (Berl); 1995 Dec; 122(3):237-43. PubMed ID: 8748393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced stimulus control and the concept of breaking point: LSD and quipazine.
    Winter JC
    Psychopharmacology (Berl); 1981; 72(2):217-8. PubMed ID: 6782615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists.
    Prosser RA; Dean RR; Edgar DM; Heller HC; Miller JD
    J Biol Rhythms; 1993; 8(1):1-16. PubMed ID: 8490207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
    Newton RA; Phipps SL; Flanigan TP; Newberry NR; Carey JE; Kumar C; McDonald B; Chen C; Elliott JM
    J Neurochem; 1996 Dec; 67(6):2521-31. PubMed ID: 8931486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of quipazine and LSD on monoamines in the rat striatum.
    Miśkiewicz M; Rokosz-Pelc A; Vetulani J
    Pol J Pharmacol Pharm; 1979; 31(5):489-92. PubMed ID: 94944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of quipazine on blood pressure in pithed rats.
    Shin YK; Svinareff P; Schmitt-Jubeau H; Schmitt H
    Arch Int Pharmacodyn Ther; 1983 Jul; 264(1):73-81. PubMed ID: 6138006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.
    Glennon RA; Young R; Rosecrans JA
    Eur J Pharmacol; 1983 Jul; 91(2-3):189-96. PubMed ID: 6617740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quipazine reduces food intake in the rat by activation of 5-HT2-receptors.
    Hewson G; Leighton GE; Hill RG; Hughes J
    Br J Pharmacol; 1988 Oct; 95(2):598-604. PubMed ID: 2906561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin1c receptor reserve in choroid plexus masks receptor subsensitivity.
    Sanders-Bush E; Breeding M
    J Pharmacol Exp Ther; 1990 Mar; 252(3):984-8. PubMed ID: 2319481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The serotonin autoreceptor: antagonism by quipazine.
    Martin LL; Sanders-Bush E
    Neuropharmacology; 1982 May; 21(5):445-50. PubMed ID: 6981071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli.
    Hirschhorn ID; Winter JC
    Psychopharmacologia; 1971; 22(1):64-71. PubMed ID: 5119576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.